Biocept Stock

Biocept Market capitalization

Delisted

The The market capitalization of Biocept (BIOC) as of Aug 4, 2026 is 4.77 M USD. In the previous year, The market capitalization was 4.77 M USD — a change of 0.00% (lower).

Market capitalization

4.77 MUSD

YoY

0.00%

Last updated:

In 2026, Biocept's market cap stood at 4.77 M USD, a 0.00% increase from the 4.77 M USD market cap in the previous year.

The Biocept Market capitalization history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Market Capitalization (undefined USD)
Date
Market Capitalization (undefined USD)
Jan 1, 2019
0.00 base
Jan 1, 2020
0.00 base
Jan 1, 2021
0.00 base
Jan 1, 2022
0.00 base
Jan 1, 2023 (e)
0.00 base
Jan 1, 2024 (e)
0.00 base
Jan 1, 2025 (e)
0.00 base
Jan 1, 2026 (e)
0.00 base
YEARMarket Capitalization (undefined USD)
2026 est -
2025 est -
2024 est -
2023 est -
2022 -
2021 -
2020 -
2019 -
2018 -
2017 -
2016 -
2015 -
2014 -
2013 -
2012 -
2011 -
Access this data via the Eulerpool API

Biocept Stock analysis

What does Biocept do? Biocept Inc is a biotechnology company based in San Diego, California. It was founded in 1997 by Michael W. Nall, an experienced entrepreneur in the field of medical diagnostics and cancer research. Biocept specializes in the development of diagnostic tests and platforms aimed at the rapid and precise identification of cancer cells in the human body. The business model of Biocept focuses on the development of cancer diagnostic tests and selling them to medical labs, physician offices, and hospitals. The company offers a range of different diagnostic products that specialize in various types and stages of cancer. One of Biocept's most important products is a liquid biopsy test that allows medical professionals to quickly and effectively detect cancer cells in patients' blood. This test is particularly significant as it enables doctors to detect cancer at an early stage, thus improving treatment options and increasing the cure rate. Additionally, Biocept offers a variety of tests targeting specific types of cancer such as breast, lung, and prostate cancer. These tests are based on the analysis of tumor DNA extracted from tumor cells in biopsies or liquid biopsies. By accurately analyzing this DNA, medical professionals can determine the specific type and stage of the cancer, thus recommending the best treatment option. In order to expand its range of diagnostic products, Biocept has also entered into partnerships with other companies and research institutions in recent years. For example, in 2017, the company entered into a collaboration with Massachusetts General Hospital to develop a new panel of liquid biopsy tests specializing in the identification of cancer cells in various tissues and organs. Biocept has experienced strong growth in recent years, and its products are now sold in a variety of countries worldwide. The company works closely with medical professionals and research institutions to continuously improve its diagnostic products and develop new tests tailored to the needs of patients with cancer. The output isn't a question, so there is no answer needed. Biocept is one of the most popular companies on Eulerpool.

Market capitalization Details

Exploring Biocept's Market Capitalization

Biocept's market capitalization represents the total dollar market value of the company’s outstanding shares of stock. It is calculated by multiplying the company's shares outstanding by the current market price of one share. This metric is a vital indicator of a company’s size, strength, and overall market value.

Year-to-Year Comparison

A yearly comparison of Biocept's market capitalization provides investors and analysts insights into its growth and valuation trends. An increase signifies market confidence and business expansion, while a decrease may point towards declining market value or business contractions.

Impact on Investments

Biocept's market capitalization plays a pivotal role in investment decisions. It aids investors in assessing the company's risk and return profiles. Larger companies are often considered more stable but may offer lower growth potential, while smaller companies might offer significant growth prospects but come with higher risk.

Interpreting Market Capitalization Fluctuations

Variations in Biocept’s market capitalization can be attributed to several factors, including changes in stock price, outstanding shares, and market sentiment. Understanding these fluctuations helps investors evaluate the company's current standing and future potential in the competitive landscape.

Frequently Asked Questions about Biocept stock

The market capitalization of Biocept is 4.77 M USD in 2026.

The market capitalization of Biocept changed from 4.77 M USD to 4.77 M USD, representing a 0.00% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The market capitalization Biocept since 2006 – with annual values, charts, and detailed analysis.

Market capitalization (German: Market capitalization, English: market capitalisation or market cap) is the calculated total value of all shares of a publicly traded company. The market capitalization of a company reflects the current market consensus on the value of the equity of a publicly traded company. It is determined by the supply and demand for the company's shares. Thus, market capitalization is significantly influenced by expectations in the stock market regarding the future earnings power of the company and, therefore, can be subject to significant fluctuations.

Number of shares * share price = market capitalization

To evaluate The market capitalization's USD, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for The market capitalization.

A 'good' USD varies by industry and company stage. On Eulerpool, you can compare The market capitalization's Biocept with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — Biocept

All Key Metrics — Biocept